Top

Published in:

Open Access 01-12-2024 | Clinical trial protocol

Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study

Authors: Antonios Bayas, Ulrich Mansmann, Begum Irmak Ön, Verena S. Hoffmann, Achim Berthele, Mark Mühlau, Markus C. Kowarik, Markus Krumbholz, Makbule Senel, Verena Steuerwald, Markus Naumann, Julia Hartberger, Martin Kerschensteiner, Eva Oswald, Christoph Ruschil, Ulf Ziemann, Hayrettin Tumani, Ioannis Vardakas, Fady Albashiti, Frank Kramer, Iñaki Soto-Rey, Helmut Spengler, Gerhard Mayer, Hans Armin Kestler, Oliver Kohlbacher, Marlien Hagedorn, Martin Boeker, Klaus Kuhn, Stefan Buchka, Florian Kohlmayer, Jan S. Kirschke, Lars Behrens, Hanna Zimmermann, Benjamin Bender, Nico Sollmann, Joachim Havla, Bernhard Hemmer, the ProVal-MS study group

Published in: Neurological Research and Practice | Issue 1/2024

Abstract

Introduction

In Multiple Sclerosis (MS), patients´ characteristics and (bio)markers that reliably predict the individual disease prognosis at disease onset are lacking. Cohort studies allow a close follow-up of MS histories and a thorough phenotyping of patients. Therefore, a multicenter cohort study was initiated to implement a wide spectrum of data and (bio)markers in newly diagnosed patients.

Methods

ProVal-MS (Prospective study to validate a multidimensional decision score that predicts treatment outcome at 24 months in untreated patients with clinically isolated syndrome or early Relapsing–Remitting-MS) is a prospective cohort study in patients with clinically isolated syndrome (CIS) or Relapsing–Remitting (RR)-MS (McDonald 2017 criteria), diagnosed within the last two years, conducted at five academic centers in Southern Germany. The collection of clinical, laboratory, imaging, and paraclinical data as well as biosamples is harmonized across centers. The primary goal is to validate (discrimination and calibration) the previously published DIFUTURE MS-Treatment Decision score (MS-TDS). The score supports clinical decision-making regarding the options of early (within 6 months after study baseline) platform medication (Interferon beta, glatiramer acetate, dimethyl/diroximel fumarate, teriflunomide), or no immediate treatment (> 6 months after baseline) of patients with early RR-MS and CIS by predicting the probability of new or enlarging lesions in cerebral magnetic resonance images (MRIs) between 6 and 24 months. Further objectives are refining the MS-TDS score and providing data to identify new markers reflecting disease course and severity. The project also provides a technical evaluation of the ProVal-MS cohort within the IT-infrastructure of the DIFUTURE consortium (Data Integration for Future Medicine) and assesses the efficacy of the data sharing techniques developed.

Perspective

Clinical cohorts provide the infrastructure to discover and to validate relevant disease-specific findings. A successful validation of the MS-TDS will add a new clinical decision tool to the armamentarium of practicing MS neurologists from which newly diagnosed MS patients may take advantage.

Trial registration ProVal-MS has been registered in the German Clinical Trials Register, `Deutsches Register Klinischer Studien` (DRKS)—ID: DRKS00014034, date of registration: 21 December 2018; https://drks.de/search/en/trial/DRKS00014034

Available only for authorised users

Aytulun, A., Cruz-Herranz, A., Aktas, O., Balcer, L. J., Balk, L., Barboni, P., Blanco, A. A., Calabresi, P. A., Costello, F., Sanchez-Dalmau, B., DeBuc, D. C., Feltgen, N., Finger, R. P., Frederiksen, J. L., Frohman, E., Frohman, T., Garway-Heath, D., Gabilondo, I., Graves, J. S., & Albrecht, P. (2021). APOSTEL 2.0 recommendations for reporting quantitative optical coherence tomography studies. Neurology, 97(2), 68–79.CrossRefPubMedPubMedCentral

Eichinger, P., Schon, S., Pongratz, V., Wiestler, H., Zhang, H., Bussas, M., Hoshi, M. M., Kirschke, J., Berthele, A., Zimmer, C., Hemmer, B., Muhlau, M., & Wiestler, B. (2019). Accuracy of unenhanced MRI in the detection of new brain lesions in multiple sclerosis. Radiology, 291(2), 429–435. https://doi.org/10.1148/radiol.2019181568CrossRefPubMed

Hapfelmeier, A., Hornung, R., & Haller, B. (2023). Efficient permutation testing of variable importance measures by the example of random forests. Computational Statistics & Data Analysis, 181, 107689.CrossRef

Hapfelmeier, A., On, B. I., Muhlau, M., Kirschke, J. S., Berthele, A., Gasperi, C., Mansmann, U., Wuschek, A., Bussas, M., Boeker, M., Bayas, A., Senel, M., Havla, J., Kowarik, M. C., Kuhn, K., Gatz, I., Spengler, H., Wiestler, B., Grundl, L., & Hemmer, B. (2023). Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis. Therapeutic Advances in Neurological Disorders, 16, 17562864231161892. https://doi.org/10.1177/17562864231161892CrossRefPubMedPubMedCentral

Hemingway, H., Croft, P., Perel, P., Hayden, J. A., Abrams, K., Timmis, A., Briggs, A., Udumyan, R., Moons, K. G., Steyerberg, E. W., Roberts, I., Schroter, S., Altman, D. G., Riley, R. D., & Group, P. (2013). Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ, 346, e5595. https://doi.org/10.1136/bmj.e5595CrossRefPubMedPubMedCentral

Hempel, S., Graham, G. D., Fu, N., Estrada, E., Chen, A. Y., Miake-Lye, I., Miles, J. N., Shanman, R., Shekelle, P. G., Beroes, J. M., & Wallin, M. T. (2017). A systematic review of modifiable risk factors in the progression of multiple sclerosis. Multiple Sclerosis, 23(4), 525–533. https://doi.org/10.1177/1352458517690270CrossRefPubMed

Hingorani, A. D., Windt, D. A., Riley, R. D., Abrams, K., Moons, K. G., Steyerberg, E. W., Schroter, S., Sauerbrei, W., Altman, D. G., Hemingway, H., & Group, P. (2013). Prognosis research strategy (PROGRESS) 4: Stratified medicine research. BMJ, 346, e5793. https://doi.org/10.1136/bmj.e5793CrossRefPubMedPubMedCentral

Hohlfeld, R., Dornmair, K., Meinl, E., & Wekerle, H. (2016). The search for the target antigens of multiple sclerosis, part 1: Autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurology, 15(2), 198–209. https://doi.org/10.1016/S1474-4422(15)00334-8CrossRefPubMed

Hohlfeld, R., Dornmair, K., Meinl, E., & Wekerle, H. (2016). The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurology, 15(3), 317–331. https://doi.org/10.1016/S1474-4422(15)00313-0CrossRefPubMed

10.

Horizon 2020 Framework Programme for Research and Innovation. Reterived 15 Aug 2023 from https://www.multiplems.eu

11.

Hothorn, T., Möst, L., & Bühlmann, P. (2018). Most likely transformations. Scandinavian Journal of Statistics, 45(1), 110–134.CrossRef

12.

Hothorn, T., & Zeileis, A. (2021). Predictive distribution modeling using transformation forests. Journal of Computational and Graphical Statistics, 30, 1181–1196.CrossRef

13.

Iacobaeus, E., Arrambide, G., Amato, M. P., Derfuss, T., Vukusic, S., Hemmer, B., Tintore, M., Brundin, L., & Group, E. F. W. (2020). Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis. https://doi.org/10.1177/1352458520925369CrossRefPubMed

14.

Kim, W., & Patsopoulos, N. A. (2022). Genetics and functional genomics of multiple sclerosis. Seminar Immunopathology, 44(1), 63–79. https://doi.org/10.1007/s00281-021-00907-3CrossRef

15.

Korepanova, N., Seibold, H., Steffen, V., & Hothorn, T. (2020). Survival forests under test: Impact of the proportional hazards assumption on prognostic and predictive forests for amyotrophic lateral sclerosis survival. Statistical Methods in Medical Research, 29(5), 1403–1419. https://doi.org/10.1177/0962280219862586CrossRefPubMed

16.

Prasser, F., Kohlbacher, O., Mansmann, U., Bauer, B., & Kuhn, K. A. (2018). Data integration for future medicine (DIFUTURE). Methods of Information in Medicine, 57(S01), e57–e65. https://doi.org/10.3414/ME17-02-0022CrossRefPubMedPubMedCentral

17.

Reeve, K., On, B. I., Havla, J., Burns, J., Gosteli-Peter, M. A., Alabsawi, A., Alayash, Z., Gotschi, A., Seibold, H., Mansmann, U., & Held, U. (2023). Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Cochrane Database Systematic Review, 9(9), CD013606. https://doi.org/10.1002/14651858.CD013606.pub2CrossRef

18.

Riley, R. D., Hayden, J. A., Steyerberg, E. W., Moons, K. G., Abrams, K., Kyzas, P. A., Malats, N., Briggs, A., Schroter, S., Altman, D. G., Hemingway, H., & Group, P. (2013). Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Medicine, 10(2), e1001380. https://doi.org/10.1371/journal.pmed.1001380CrossRefPubMedPubMedCentral

19.

Rotstein, D., & Montalban, X. (2019). Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nature Reviews. Neurology, 15(5), 287–300. https://doi.org/10.1038/s41582-019-0170-8CrossRefPubMed

20.

Schippling, S., Balk, L. J., Costello, F., Albrecht, P., Balcer, L., Calabresi, P. A., Frederiksen, J. L., Frohman, E., Green, A. J., Klistorner, A., Outteryck, O., Paul, F., Plant, G. T., Traber, G., Vermersch, P., Villoslada, P., Wolf, S., & Petzold, A. (2015). Quality control for retinal OCT in multiple sclerosis: Validation of the OSCAR-IB criteria. Multiple Sclerosis, 21(2), 163–170. https://doi.org/10.1177/1352458514538110CrossRefPubMed

21.

Steyerberg, E. W. (2019.). Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. (2nd edition ed.).

22.

Steyerberg, E. W., Moons, K. G., van der Windt, D. A., Hayden, J. A., Perel, P., Schroter, S., Riley, R. D., Hemingway, H., Altman, D. G., & Group, P. (2013). Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Medicine, 10(2), e1001381. https://doi.org/10.1371/journal.pmed.1001381CrossRefPubMedPubMedCentral

23.

Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., Fujihara, K., Galetta, S. L., Hartung, H. P., Kappos, L., Lublin, F. D., Marrie, R. A., Miller, A. E., Miller, D. H., Montalban, X., & Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, 17(2), 162–173. https://doi.org/10.1016/S1474-4422(17)30470-2CrossRefPubMed

24.

Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018). Multiple sclerosis. Lancet, 391(10130), 1622–1636. https://doi.org/10.1016/S0140-6736(18)30481-1CrossRefPubMed

25.

Wiltgen, T., McGinnis, J., Schlaeger, S., Voon, C., Berthele, A., Bischl, D., Grundl, L., Will, N., Metz, M., Schinz, D., Sepp, D., Prucker, P., Schmitz-Koep, B., Zimmer, C., Menze, B., Rueckert, D., Hemmer, B., Kirschke, J., Muhlau, M., & Wiestler, B. (2023). LST-AI: a Deep Learning Ensemble for Accurate MS Lesion Segmentation. medRxiv. https://doi.org/10.1101/2023.11.23.23298966

26.

Wolfson, M., Wallace, S. E., Masca, N., Rowe, G., Sheehan, N. A., Ferretti, V., LaFlamme, P., Tobin, M. D., Macleod, J., Little, J., Fortier, I., Knoppers, B. M., & Burton, P. R. (2010). DataSHIELD: Resolving a conflict in contemporary bioscience–performing a pooled analysis of individual-level data without sharing the data. International Journal of Epidemiology, 39(5), 1372–1382. https://doi.org/10.1093/ije/dyq111CrossRefPubMedPubMedCentral

Title: Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study
Authors: Antonios Bayas
Ulrich Mansmann
Begum Irmak Ön
Verena S. Hoffmann
Achim Berthele
Mark Mühlau
Markus C. Kowarik
Markus Krumbholz
Makbule Senel
Verena Steuerwald
Markus Naumann
Julia Hartberger
Martin Kerschensteiner
Eva Oswald
Christoph Ruschil
Ulf Ziemann
Hayrettin Tumani
Ioannis Vardakas
Fady Albashiti
Frank Kramer
Iñaki Soto-Rey
Helmut Spengler
Gerhard Mayer
Hans Armin Kestler
Oliver Kohlbacher
Marlien Hagedorn
Martin Boeker
Klaus Kuhn
Stefan Buchka
Florian Kohlmayer
Jan S. Kirschke
Lars Behrens
Hanna Zimmermann
Benjamin Bender
Nico Sollmann
Joachim Havla
Bernhard Hemmer
the ProVal-MS study group
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Neurological Research and Practice / Issue 1/2024
Electronic ISSN: 2524-3489
DOI: https://doi.org/10.1186/s42466-024-00310-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study

Abstract

Introduction

Methods

Perspective

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Perspective

Please log in to get access to this content

Other articles of this Issue 1/2024

Repetitive head injuries in German American football players do not change blood-based biomarker candidates for CTE during a single season

Creative thinking and cognitive estimation in Parkinson’s disease

Management of status epilepticus in pregnancy: a clinician survey

Neuropathological hints from CSF and serum biomarkers in corticobasal syndrome (CBS): a systematic review

Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review

Cognitive disorders in advanced Parkinson’s disease: challenges in the diagnosis of delirium